GlobeNewswireNOV 72 min read$IMCR

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity ...

Original reporting

GlobeNewswire · Immunocore Holdings plc

Published Nov 7, 2025, 1:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 8, 2025, 1:01 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting — source image — Source · www.globenewswire.com

Decision brief

The 30-second read

$IMCRNeutralLow

Why it matters

The presentation of Phase 1 data indicates ongoing clinical development but does not provide immediate catalysts for stock movement.

Market read

The news is of moderate relevance to biotech investors; overall market impact is limited.

What to watch

Potential future developments or partnership announcements could alter the impact trajectory.

Relevance 6/10Timing: Long-term relevance; short-term trading implications are minimal.

Background

Immunocore is advancing a hepatitis B therapeutic candidate, IMC-I109V, with recent Phase 1 data presented at AASLD's The Liver Meeting.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IMCRNeutralMedium confidence

Context

Low relevance due to moderate relevance score (0.145291)

Expected impact

Negligible impact on IMCR stock price in the short term.

Evidence & confidence

The relevance score is low, and the sentiment is neutral, indicating limited market influence.

Market effects

Sector

Potential positive sentiment for biotech and life sciences sectors due to ongoing clinical development.

Regional

Limited regional impact; news pertains to a specific company's clinical trial data.

Global

Minimal global market impact given the specificity of the news.

Counterpoint

What could challenge this read

Positive clinical data could eventually lead to positive valuation adjustments if subsequent trials are successful.

Key entities

Company
Immunocore Holdings plc
A biotechnology company focused on immunotherapies.

Read at source ← All news

SEP 14

$IMCRMedAI 8/10

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Regulation FD Disclosure. Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US,

SEC EDGAR 8-K2 min

AUG 7

$IMCRMed

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Immunocore Holdings (IMCR) reported Q2 2026 EPS of a loss of $0.02, wider than the Zacks Consensus loss of $0.01. Revenue rose 18.3% Y/Y to $115.9 million, beating the $114 million estimate, driven by Kimmtrak net product sales. Management cited about $6 million of US distributor inventory stocking as a Q3 headwind.

tradingview.com4 min

AUG 6

$IMCRMed

Immunocore reports second quarter financial results and provides a business update

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing

SEC EDGAR 8-K7 min

MAY 31

$IMCRMedAI 9/10

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore reported updated Phase 1/2 brenetafusp data in heavily pretreated HLA-A*02:01-positive advanced melanoma at ASCO 2026. In 66 monotherapy patients, 6-month OS was 87% and disease control rate 52% (ORR 12%); median OS was 14.3 months. The company said results supported a 160 mcg dose for Phase 3 PRISM-MEL-301 and that safety was generally well tolerated.

manilatimes.net5 min

OCT 25

$METAMed

Meta’s AI commitments surge to US$825 billion, testing financing power

Meta Platforms' AI infrastructure spending is causing financial strain. Free cash flow turned negative in Q3 2026, and future commitments reached $825 billion. This reflects rising pressure on the company's financing power, according to Bloomberg.

digitimes.com2 min

OCT 24

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

investing.com2 min